Clinical Trial Update: Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of trastuzumab plus ixabepilone for HER2-positive metastatic breast cancer was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Ixabepilone (ixabepilone)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-02-06